share_log

广生堂(300436.SZ):乙肝治疗创新药GST-HG141获得II期临床研究总结报告

Fujian Cosunter Pharmaceutical (300436.SZ): The phase II clinical study summary report of innovative drug GST-HG141 for the treatment of hepatitis B

Gelonghui Finance ·  Sep 8 04:38

On September 8th, Fujian Cosunter Pharmaceutical (300436.SZ) announced that its innovative hepatitis B treatment drug GST-HG141 has completed phase II clinical trials for Chronic Hepatitis B Low Viral Load (LLV) and recently received the research summary report of the phase II clinical trial. The research results show that GST-HG141 tablets have good safety and significant efficacy for patients with chronic hepatitis B low viral load, with a significant inhibitory effect on HBVDNA compared to the current clinical recommended nucleos(t)ide analog monotherapy control group. It has been confirmed in hepatitis B patients that it further inhibits HBVDNA replication and potential depletion of cccDNA based on nucleos(t)ide analog drug treatment, achieving the expected clinical research goals with outstanding data.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment